SurModics signs license agreement for UV treatment technology
SurModics Pharmaceuticals, a Birmingham subsidiary of SurModics Inc., has agreed to license a biodegradable polymer implant technology being developed to treat sun-induced skin disorders to an Australian pharmaceutical firm.
SurModics licensed the SCENESSE implant formula to Australian-based Clinuvel Pharmaceuticals. The two companies have collaborated on developing the formula that is a prophylactic treatment for a range of UV and light-related skin disorders for several years.
“We are very pleased to announce the execution of this important license agreement with Clinuvel,” said Phil Ankeny, interim CEO of SurModics. “This announcement demonstrates the value of our sustained drug delivery technologies and reinforces how we partner with our customers to develop and bring to market compelling products that leverage our core technologies cash advance loans.”
Drugs released from the prophylactic causes melanin production in the skin to protect from ultraviolet rays. Estimates from the Royal Bank of Scotland projects the treatment could impact as many as 7 million people worldwide, according to a release from SurModics.
“Today’s announcement represents a natural progression of our relationship with Clinuvel,” said Arthur J. Tipton, senior vice president and chief scientific officer of SurModics. “Together, our teams have solved numerous scientific and technical issues over the years culminating in the signing of this licensing agreement. Clinuvel’s product provides a novel way to treat serious skin disorders.”